Les publications

• Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes. Billaud A, Chevalier LM, Augereau P, Frenel JS, Passot C, Campone M, Morel A. Genome Med. 2021; 13(1):174.
• Predicting clinical outcomes of ovarian cancer patients: deep survival models and transfer learning. Spirina Menand, E. S., Jrad, N., Marion, J. M., Morel, A., & Chauvet, P.  ESREL (2021). 371.
• A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation. Pinquie F, Cortot AB, Chevalier LM, Morel A, Sandrini J, Guguen C, Morvan B, Molinier O. Clin Lung Cancer. 2021; 13:S1525-7304(21)00142-X.
• TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis. Cordel N, Derambure C, Coutant S, Mariette X, Jullien D, Debarbieux S, Chosidow O, Meyer A, Bessis D, Joly P, Mathian A, Levesque H, Sabourin JC, Tournier I, Boyer O; OncoMyositis Study group. Rheumatology (Oxford). 2021; 60(12):5863-5867.
• Blood functional assay for rapid clinical interpretation of germline TP53 variants. Raad S, Rolain M, Coutant S, Derambure C, Lanos R, Charbonnier F, Bou J, Bouvignies E, Lienard G, Vasseur S, Farrell M, Ingster O, Baert Desurmont S, Kasper E, Bougeard G, Frébourg T, Tournier I. J Med Genet. 2021;5 8(12):796-805.
• Mathian A, Levesque H, Sabourin JC, Tournier I, Boyer O; OncoMyositis Study group. Rheumatology (Oxford). 2021; 60(12):5863-5867.
• Blood functional assay for rapid clinical interpretation of germline TP53 variants. Raad S, Rolain M, Coutant S, Derambure C, Lanos R, Charbonnier F, Bou J, Bouvignies E, Lienard G, Vasseur S, Farrell M, Ingster O, Baert Desurmont S, Kasper E, Bougeard G, Frébourg T, Tournier I. J Med Genet. 2021;5 8(12):796-805.
• Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components. Raoul JL, Heymann MF, Dumont F, Morel A, Senellart H, Bertucci F. Front Oncol. 2021; 11:646992.
• Detection of copy-number variations from NGS data using read depth information: a diagnostic performance evaluation. Quenez O, Cassinari K, Coutant S, Lecoquierre F, Le Guennec K, Rousseau S, Richard AC, Vasseur S, Bouvignies E, Bou J, Lienard G, Manase S, Fourneaux S, Drouot N, Nguyen-Viet V, Vezain M, Chambon P, Joly-Helas G, Le Meur N, Castelain M, Boland A, Deleuze JF; FREX Consortium, Tournier I, Charbonnier F, Kasper E, Bougeard G, Frebourg T, Saugier-Veber P, Baert-Desurmont S, Campion D, Rovelet-Lecrux A, Nicolas G. Eur J Hum Genet. 2021; 29(1):99-109.

• L’instabilité génomique, paramètre limitant l’efficacité des thérapies ciblées en oncologie [Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology].  Billaud A, Chevalier LM, Campone M, Morel A, Bigot F. Bull Cancer. 2020; 107(11):1161-1170.
• Assessment of branch point prediction tools to predict physiological branch points and their alteration by variants.  Leman R, Tubeuf H, Raad S, Tournier I, Derambure C, Lanos R, Gaildrat P, Castelain G, Hauchard J, Killian A, Baert-Desurmont S, Legros A, Goardon N, Quesnelle C, Ricou A, Castera L, Vaur D, Le Gac G, Ka C, Fichou Y, Bonnet-Dorion F, Sevenet N, Guillaud-Bataille M, Boutry-Kryza N, Schultz I, Caux-Moncoutier V, Rossing M, Walker LC, Spurdle AB, Houdayer C, Martins A, Krieger S. BMC Genomics. 2020; 21(1):86.
• Checkpoint inhibitors in metastatic papillary renal cell carcinoma de Vries-Brilland M, McDermott DF, Suárez C, Powles T, Gross-Goupil M, Ravaud A, Flippot R, Escudier B, Albigès L.. Cancer Treat Rev. 2021 Sep;99:102228.
• Non-Small-Cell Lung Cancer-Sensitive Detection of the p.Thr790Met EGFR Alteration by Preamplification before PNA-Mediated PCR Clamping and Pyrosequencing. Billaud A, Verriele V, Dauvé J, Chevalier LM, Morel A. Diagnostics (Basel). 2020; 10(8):527.
• Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study de Vries-Brilland M, Gross-Goupil M, Seegers V, Boughalem E, Beuselinck B, Thibault C, Chevreau C, Ladoire S, Barthélémy P, Negrier S, Borchiellini D, Huillard O, Geoffrois L, Gravis G, Saldana C, Thiery-Vuillemin A, Escudier B, Ravaud A, Albiges L.. Eur J Cancer. 2020 Sep;136:76-83.
• Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors. Chevalier LM, Billaud A, Fronteau S, Dauvé J, Patsouris A, Verriele V, Morel A. Mol Diagn Ther. 2020; 24(2):233-243.
• Caractérisation moléculaire de l’EGFR dans les cancers bronchiques non à petites cellules : étude prospective comparative des technologies NGS et automate Idylla [EGFR molecular characterization in non-small cell bronchic cancer: comparative prospective study by NGS and Idylla platform technologies]. Chevalier LM, Billaud A, Passot C, Renoult A, Bigot F, Verrièle V, Morel A. Ann Pathol. 2020; 40(5):389-400.

• Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature. de Vries-Brilland M, Sionneau B, Dutriaux C, Blay JY, Ravaud A, Gross-Goupil M.. Clin Genitourin Cancer. 2019 Aug;17(4):e721-e723.
• Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors. Eur J Cancer. 2019; 116:86-97.
• The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells. Riahi-Chebbi I, Souid S, Othman H, Haoues M, Karoui H, Morel A, Srairi-Abid N, Essafi M, Essafi-Benkhadir K. Sci Rep. 2019; 9(1):195.

• Optimization of the diagnosis of inherited colorectal cancer using NGS and capture of exonic and intronic sequences of panel genes. Baert-Desurmont S, Coutant S, Charbonnier F, Macquere P, Lecoquierre F, Schwartz M, Blanluet M, Vezain M, Lanos R, Quenez O, Bou J, Bouvignies E, Fourneaux S, Manase S, Vasseur S, Mauillon J, Gerard M, Marlin R, Bougeard G, Tinat J, Frebourg T, Tournier I. Eur J Hum Genet. 2018; 26(11):1597-1602.
• Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. Renaux-Petel M, Charbonnier F, Théry JC, Fermey P, Lienard G, Bou J, Coutant S, Vezain M, Kasper E, Fourneaux S, Manase S, Blanluet M, Leheup B, Mansuy L, Champigneulle J, Chappé C, Longy M, Sévenet N, Paillerets BB, Guerrini-Rousseau L, Brugières L, Caron O, Sabourin JC, Tournier I, Baert-Desurmont S, Frébourg T, Bougeard G. J Med Genet. 2018; 55(3):173-180.

• A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.  Boisdron-Celle M, Metges JP, Capitain O, Adenis A, Raoul JL, Lecomte T, Lam YH, Faroux R, Masliah C, Poirier AL, Berger V, Morel A, Gamelin E. Semin Oncol. 2017; 44(1):24-33.
• Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach. Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E. Semin Oncol. 2017; 44(1):13-23.
• Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Zerdoumi Y, Lanos R, Raad S, Flaman JM, Bougeard G, Frebourg T, Tournier I. Hum Mol Genet. 2017; 26(14):2591-2602.
• Familial solitary chondrosarcoma resulting from germline EXT2 mutation. Heddar A, Fermey P, Coutant S, Angot E, Sabourin JC, Michelin P, Parodi N, Charbonnier F, Vezain M, Bougeard G, Baert-Desurmont S, Frébourg T, Tournier I. Genes Chromosomes Cancer. 2017; 56(2):128-134.

• Clinical, histological, and molecular risk factors for cancer recurrence in patients with stage II colon cancer. Touchefeu Y, Provost-Dewitte M, Lecomte T, Morel A, Valo I, Mosnier JF, Bossard C, Eugène J, Duchalais E, Chetritt J, Guyetant S, Bézieau S, Senellart H, Caulet M, Cauchin E, Matysiak-Budnik T. Eur J Gastroenterol Hepatol. 2016; 28(12):1394-1399.

• Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics. Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T. 2015; 16(18):2035-43.

• IL-26 inhibits hepatitis C virus replication in hepatocytes. Élodie Beaumont, Vincent Larochette, Laurence Preisser, Charline Miot, Pascale Pignon, Simon Blanchard, Björn-Thore Hansen, Jonathan Dauvé, Caroline Poli, Minna M Poranen, Patricia Lamourette, Marc Plaisance, Alain Morel, Helmut Fickenscher, Pascale Jeannin, Philippe Roingeard, Yves Delneste. Journal of Hepatology  dec 2021
• Acetoacetate protects macrophages from lactic acidosis-induced mitochondrial dysfunction by metabolic reprograming. Adam C, Paolini L, Gueguen N, Mabilleau G, Preisser L, Blanchard S, Pignon P, Manero F, Le Mao M, Morel A, Reynier P, Beauvillain C, Delneste Y, Procaccio V, Jeannin P. Nat Commun. 2021; 12(1):7115.
• Lactic Acidosis Together with GM-CSF and M-CSF Induces Human Macrophages toward an Inflammatory Protumor Phenotype. Paolini L, Adam C, Beauvillain C, Preisser L, Blanchard S, Pignon P, Seegers V, Chevalier LM, Campone M, Wernert R, Verrielle V, Raro P, Ifrah N, Lavoué V, Descamps P, Morel A, Catros V, Tcherkez G, Lenaers G, Bocca C, Kouassi Nzoughet J, Procaccio V, Delneste Y, Jeannin P. Cancer Immunol Res. 2020; (3):383-395.
• IL-26 Confers Proinflammatory Properties to Extracellular DNA. Poli C, Augusto JF, Dauvé J, Adam C, Preisser L, Larochette V, Pignon P, Savina A, Blanchard S, Subra JF, Chevailler A, Procaccio V, Croué A, Créminon C, Morel A, Delneste Y, Fickenscher H, Jeannin P. J Immunol. 2017; 198(9):3650-3661.

Retour à la page d'accueil